Stereochemistry | ABSOLUTE |
Molecular Formula | C29H40O9 |
Molecular Weight | 532.6225 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 13 / 13 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@]3([H])[C@]([H])(CC[C@]4(C)[C@H](CC[C@]34O)C5=CC(=O)OC5)[C@]1(C[C@@]6([H])O[C@@]7(O)[C@@H](O)C[C@@H](C)O[C@@]7([H])O[C@]6([H])C2)C=O
InChI
InChIKey=OWPWFVVPBYFKBG-NYVHBPEFSA-N
InChI=1S/C29H40O9/c1-15-9-23(31)29(34)25(36-15)37-21-11-17-3-4-20-19(27(17,14-30)12-22(21)38-29)5-7-26(2)18(6-8-28(20,26)33)16-10-24(32)35-13-16/h10,14-15,17-23,25,31,33-34H,3-9,11-13H2,1-2H3/t15-,17+,18-,19+,20-,21-,22-,23+,25+,26-,27-,28+,29+/m1/s1
Molecular Formula | C29H40O9 |
Molecular Weight | 532.6225 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 13 / 13 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Patents
Sample Use Guides
Calotropin was administered through gavage 25 mg/kg body wt. each day for a period of 30 days to male gerbils and rabbits
Route of Administration:
Oral